TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Year: 2025
Type: article
Abstract: Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine colorectal cancer organoid-based transplantation model, we identified TYK2 as a key factor controlling CRLM. Evaluation of the effects of Tyk2 deletion in different subsets of immune cells and in colorectal cancer cells demonstrated that TYK2 was not required in cancer cells, macrophages, NK cells, T cells, or Kupffer cells. Instead, TYK2 controlled CRLM via a dendritic cell-dependent mechanism that relied on MHC-I-mediated cross-presentation of antigens to CD8+ T cells. Analysis of single-cell RNA sequencing data from primary colorectal cancer and CRLM revealed that TYK2 was predominantly expressed in a dendritic cell population destined to present antigens in tumor-draining lymph nodes. Treatment with the TYK2 inhibitor deucravacitinib, which is approved by the FDA for treating plaque psoriasis and is under clinical investigation for other autoimmune diseases, promoted CRLM. Together, these data demonstrate that TYK2 controls CRLM immunosurveillance, which should be carefully considered when treating patients with TYK2 inhibitors. SIGNIFICANCE: TYK2 restricts the metastasis of colorectal tumors to the liver by supporting dendritic cell-dependent induction of antitumor CD8+ T cells, which could impact the use of TYK2 inhibitors in patients.
Source: Cancer Research
Authors: Bernadette Mödl, Daniela Zwolanek, Katharina Schwertner, Dana Krauß, Stefan Moritsch, Irene Scharf, Anne-Sophie Ebner, Veronica Moreno-Viedma, Cristiano de Sa Fernandes, Philipp Novoszel, Martin Holcmann, Martina Hammer, Nunzia Matrone, Michaela Schlederer, Birgit Strobl, Emilio Casanova, Caroline Lassnig, Dietmar Herndler-Brandstetter, Lukas Kenner, Mathias Müller, Maria Sibilia, Robert Eferl
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: G1227914001, G1234419791, JAK inhibitors in KRAS driven Lung Adenocarcinoma, Deciphering breast cancer heterogeneity and tumor microenvironment with correlative imaging, STAT1 suppresses KRAS Mutated Lung Adenocarcinoma, G2760142331, G3685198513, G4178063278, G4241193532, G444464903, Therapeutic targeting of EGFR in colorectal cancer as a novel approach to predict and enhance tumor antigenicity and response to checkpoint inhibitors, PDGFRB function in lymphoma progression, Inflammation and Immunity, G6498066335, Afatinib in KRAS driven Lung Adenocarcinoma, Genetic Dissection of IL-6 signalin in prostate cancerogenesis, G8268674276, G864014265, Role of TCR signalling in the genesis of ALCL
OpenAlex ID: W4414465665